1. Home
  2. RYTM

RYTM

Rhythm Pharmaceuticals Inc.

Logo Rhythm Pharmaceuticals Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.

Founded: 2008 Country:
United States
United States
Employees: N/A City: BOSTON
Market Cap: 2.5B IPO Year: 2017
Target Price: $47.40 AVG Volume (30 days): 607.3K
Analyst Decision: Strong Buy Number of Analysts: 5
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -3.20 EPS Growth: N/A
52 Week Low/High: $15.50 - $52.57 Next Earning Date: 04-30-2024
Revenue: $77,428,000 Revenue Growth: 227.56%
Revenue Growth (this year): 77.78% Revenue Growth (next year): 54.57%

Share on Social Networks: